JP2014530627A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530627A5
JP2014530627A5 JP2014537358A JP2014537358A JP2014530627A5 JP 2014530627 A5 JP2014530627 A5 JP 2014530627A5 JP 2014537358 A JP2014537358 A JP 2014537358A JP 2014537358 A JP2014537358 A JP 2014537358A JP 2014530627 A5 JP2014530627 A5 JP 2014530627A5
Authority
JP
Japan
Prior art keywords
melanoma
cell
vaccine
cells
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014537358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530627A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530627A publication Critical patent/JP2014530627A/ja
Publication of JP2014530627A5 publication Critical patent/JP2014530627A5/ja
Pending legal-status Critical Current

Links

JP2014537358A 2011-10-20 2012-10-22 抗原提示癌ワクチン Pending JP2014530627A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549,681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02

Publications (2)

Publication Number Publication Date
JP2014530627A JP2014530627A (ja) 2014-11-20
JP2014530627A5 true JP2014530627A5 (enExample) 2016-02-25

Family

ID=48141460

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014537358A Pending JP2014530627A (ja) 2011-10-20 2012-10-22 抗原提示癌ワクチン
JP2014537355A Pending JP2014533938A (ja) 2011-10-20 2012-10-22 γインターフェロンを用いた抗原提示癌ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014537355A Pending JP2014533938A (ja) 2011-10-20 2012-10-22 γインターフェロンを用いた抗原提示癌ワクチン

Country Status (11)

Country Link
US (2) US9555058B2 (enExample)
EP (2) EP2768519A4 (enExample)
JP (2) JP2014530627A (enExample)
KR (2) KR20150016200A (enExample)
CN (5) CN105288602A (enExample)
AU (2) AU2012325764A1 (enExample)
CA (2) CA2852960A1 (enExample)
HK (2) HK1201176A1 (enExample)
IL (2) IL232173A0 (enExample)
SG (4) SG11201401631VA (enExample)
WO (2) WO2013059784A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
CN105288602A (zh) 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにher2およびher3を遮断するための併用療法
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
CA3053939A1 (en) * 2017-02-17 2018-08-23 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598998B1 (en) * 1992-09-07 2004-05-19 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies reacting with the ganglioside GM2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
AU8026800A (en) 1999-10-15 2001-04-30 Baylor Research Institute Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DK1448229T3 (da) * 2001-11-29 2010-03-08 Dandrit Biotech As Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
US20060140983A1 (en) * 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
EP1951318B1 (en) * 2005-11-07 2012-10-17 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP2630968A1 (en) * 2006-06-30 2013-08-28 Baylor Research Institute Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
CN105288602A (zh) 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗

Similar Documents

Publication Publication Date Title
JP2014533938A5 (enExample)
Hailemichael et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Padte et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates
Hope et al. Striking a balance—cellular and molecular drivers of memory T cell development and responses to chronic stimulation
PL2102331T3 (pl) Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
MX377144B (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
MX2020011674A (es) Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
JP2010514455A5 (enExample)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2018007295A (es) Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
JP2014514927A5 (enExample)
WO2012054509A3 (en) Discovery of regulatory t cells programmed to suppress an immune response
TR201905447T4 (tr) Yeni mhc bağımsız tümörle ilişkili antijenler.
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
JP2015506698A5 (enExample)
US8076132B2 (en) Dendritic cell tumor injection (DCTI) therapy
Yang et al. HCA587 protein vaccine induces specific antitumor immunity mediated by CD4+ T-cells expressing granzyme B in a mouse model of melanoma
MX2020004757A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
RU2012103822A (ru) Способ генерации антиген-специфических цитотоксических клеток с активностью против клеток рака яичника
Ota et al. Vaccination of acute leukemia patients with WT1 peptide-pulsed dendritic cells induces immunological and clinical responses: a pilot study
Schmittling Data from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Yun et al. Costimulate moleculars amplified the DRibble mediated T cells response
Faries et al. Intralesional Bacille Calmette-Guerin in melanoma: a forgotten modality of in situ immunization